

Edgar Filing: TUTOGEN MEDICAL INC - Form NT 10-Q/A

TUTOGEN MEDICAL INC  
Form NT 10-Q/A  
May 17, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
OMB APPROVAL

-----  
OMB Number: 3235-0058  
Expires: March 31, 2006  
Estimated average burden hours  
per response.....2.50  
-----

FORM 12B-25/A

NOTIFICATION OF LATE FILING

-----  
SEC FILE NUMBER

-----  
CUSIP NUMBERs  
019855 30 3  
-----

(CHECK ONE):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  
 Form N-SAR  Form N-CSR

For Period  
Ended: March 31, 2006  
-----

Transition Report on Form 10-K  
 Transition Report on Form 20-F  
 Transition Report on Form 11-K  
 Transition Report on Form 10-Q  
 Transition Report on Form N-SAR  
For the Transition Period  
Ended:  
-----

READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.

-----  
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS  
VERIFIED ANY INFORMATION CONTAINED HEREIN.  
-----

If the notification relates to a portion of the filing checked above, identify  
the Item(s) to which the notification relates:

PART I -- REGISTRANT INFORMATION

Tutogen Medical, Inc.  
-----

Full Name of Registrant

Edgar Filing: TUTOGEN MEDICAL INC - Form NT 10-Q/A

N/A

-----  
Former Name if Applicable

One Progress Boulevard

-----  
Address of Principal Executive Office (STREET AND NUMBER)

Alachua, Florida 32615

-----  
City, State and Zip Code

PART II -- RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- | (a) The reason described in reasonable detail in Part III of this form  
| could not be eliminated without unreasonable effort or expense  
|
- | (b) The subject annual report, semi-annual report, transition report on  
| Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or  
| portion thereof, will be filed on or before the  
| [X] | fifteenth calendar day following the prescribed due date; or the  
| subject quarterly report or transition report on Form 10-Q, or  
| portion thereof, will be filed on or before the fifth calendar day  
| following the prescribed due date; and  
|
- | (c) The accountant's statement or other exhibit required by Rule  
| 12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Tutogen Medical, Inc. (the "Company") has announced that it is conducting a review of its previously reported financial statements for the fiscal years ended September 30, 2003, 2004 and 2005, and the 2006 first fiscal quarter ended December 31, 2005, as a result of an error discovered by management during its second fiscal quarter review in the accounting of actual costs associated with inventory purchased from its German subsidiary. Management presented its findings to the Company's Audit Committee and is continuing to examine the Company's accounting for such transactions. The Company anticipates a restatement of such financial statements. As a result, the Company was not in position to timely file its Quarterly Report on Form 10-Q for the second quarter ended March 31, 2006 by May 15, 2006, and may not file such Quarterly Report within the 5-day extension period permitted by Rule 12b-25 under the Securities Exchange Act of 1934, as amended.

(Attach extra Sheets if Needed)

Edgar Filing: TUTOGEN MEDICAL INC - Form NT 10-Q/A

SEC 1344 PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION  
(03-05) CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM  
DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

PART IV -- OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

L. Robert Johnston, Jr. (386) 462-0402  
-----  
(Name) (Area Code) (Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  Yes  No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Based on preliminary information, as a result of the error, inventory in each fiscal years 2003, 2004, and 2005 and the 2006 first fiscal quarter ended December 31, 2005 was overstated by up to \$800,000. Additionally, as a result of selling the intercompany inventory at a higher cost than actual cost, earnings for the cumulative period from October 1, 2003 to December 31, 2005 were understated by approximately \$300,000 to \$1,000,000. The accounting error is not expected to have an adverse effect on the Company's business outlook for future fiscal periods nor impact the Company's future cash flows from operations.

To reflect the Company's revised financial information, including the preliminary adjustments described above, the Company anticipates that its previously issued financial statements for fiscal years ended September 30, 2003, 2004, and 2005 contained in the Company's Annual Report on Form 10-K for such years, and the Company's quarterly financial statements for the 2006 first quarter ended December 31, 2005 contained in the Company's Quarterly Report on Form 10-Q will be restated in amended filings with the Securities and Exchange Commission (the "SEC").

For more information regarding these matters, please see our Current Report on Form 8-K, dated May 16, 2006, filed with the SEC.

The foregoing statements and estimates contained herein that disclose the Company's or its management's intentions, expectations or predictions of the future, including expected restatement adjustments to previously issued consolidated financial statements are forward-looking statements. The actual amounts and effects of the Company's restatement adjustments, and the actual dates for the Company's amended SEC filings, could differ materially from those projected in such forward-looking statements. [GRAPHIC OMITTED]

Edgar Filing: TUTOGEN MEDICAL INC - Form NT 10-Q/A

-----  
TUTOGEN MEDICAL, INC.  
-----

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 16, 2006

By: /s/ Guy L. Mayer

-----  
Guy L. Mayer  
Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

-----  
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).  
-----